

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/158385 A1

(51) International Patent Classification:

A61K 47/60 (2017.01) *A61P 37/06* (2006.01)
A61K 38/20 (2006.01) *A61P 43/00* (2006.01)
A61K 48/00 (2006.01) *C12N 15/864* (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2025/050828

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

24 January 2025 (24.01.2025)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/625,113 25 January 2024 (25.01.2024) US
63/641,189 01 May 2024 (01.05.2024) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 450
Water Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **CHOUDHURY, Sourav Roy**; c/o Sanofi,
450 Water Street, Cambridge, Massachusetts 02141 (US).
MOTWANI, Mona; c/o Sanofi, 450 Water Street, Cam-
bridge, Massachusetts 02141 (US). **MUELLER, Chris-
tian**; c/o Sanofi, 450 Water Street, Cambridge, Mass-
achusetts 02141 (US). **PARK, Mincheol**; c/o Sanofi,
450 Water Street, Cambridge, Massachusetts 02141 (US).
GWALANI, Lavesb; c/o Sanofi, 450 Water Street, Cam-
bridge, Massachusetts 02141 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: PEGYLATED IL-2 FOR SUPPRESSING ADAPTIVE IMMUNE RESPONSE TO GENE THERAPY

(57) Abstract: The disclosure relates to methods of delivering a gene therapy agent to a subject, treating an individual in need of a gene therapy agent, increasing expression of a gene therapy agent, reducing an immune response to a gene therapy agent, and preventing immune-related adverse events in a subject by administering a gene therapy agent and an IL-2 conjugate to the subject. The IL-2 conjugate has at least one amino acid residue replaced by an unnatural amino acid linked to a conjugating moiety. The disclosure further relates to methods of selecting a subject for treatment with a gene therapy agent and an IL-2 conjugate.

WO 2025/158385 A1